CN117915915A - 因子b抑制剂用于治疗年龄相关性黄斑变性的用途 - Google Patents
因子b抑制剂用于治疗年龄相关性黄斑变性的用途 Download PDFInfo
- Publication number
- CN117915915A CN117915915A CN202280060138.3A CN202280060138A CN117915915A CN 117915915 A CN117915915 A CN 117915915A CN 202280060138 A CN202280060138 A CN 202280060138A CN 117915915 A CN117915915 A CN 117915915A
- Authority
- CN
- China
- Prior art keywords
- administration
- ipracopan
- administered
- reduces
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241169P | 2021-09-07 | 2021-09-07 | |
| US63/241,169 | 2021-09-07 | ||
| PCT/IB2022/058275 WO2023037218A1 (en) | 2021-09-07 | 2022-09-02 | Use of factor b inhibitors for the treatment of age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117915915A true CN117915915A (zh) | 2024-04-19 |
Family
ID=83457168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280060138.3A Pending CN117915915A (zh) | 2021-09-07 | 2022-09-02 | 因子b抑制剂用于治疗年龄相关性黄斑变性的用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240398779A1 (enExample) |
| EP (1) | EP4398906A1 (enExample) |
| JP (1) | JP2024530344A (enExample) |
| CN (1) | CN117915915A (enExample) |
| WO (1) | WO2023037218A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
-
2022
- 2022-09-02 JP JP2024514000A patent/JP2024530344A/ja active Pending
- 2022-09-02 US US18/689,933 patent/US20240398779A1/en active Pending
- 2022-09-02 WO PCT/IB2022/058275 patent/WO2023037218A1/en not_active Ceased
- 2022-09-02 EP EP22777708.3A patent/EP4398906A1/en active Pending
- 2022-09-02 CN CN202280060138.3A patent/CN117915915A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4398906A1 (en) | 2024-07-17 |
| WO2023037218A1 (en) | 2023-03-16 |
| US20240398779A1 (en) | 2024-12-05 |
| JP2024530344A (ja) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Müskens et al. | Systemic antihypertensive medication and incident open-angle glaucoma | |
| Nguyen et al. | Vascular endothelial growth factor is a critical stimulus for diabetic macular edema | |
| Rosenfeld et al. | Maximum tolerated dose of a humanized anti–vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration | |
| US20220211691A1 (en) | Treatment of dry eye disease | |
| Boopathiraj et al. | Recent updates on the diagnosis and management of age-related macular degeneration | |
| Fawzi et al. | Central serous chorioretinopathy after solid organ transplantation | |
| Kawali et al. | Acute depigmentation of the iris: a retrospective analysis of 22 cases | |
| WO2021252647A1 (en) | Methods of improving retina-associated disease outcome using ccr3-inhibitors | |
| JP7615139B2 (ja) | 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤 | |
| Priluck et al. | Ischemic retinal events after COVID-19 vaccination | |
| US20240398779A1 (en) | Use of factor b inhibitors for the treatment of age-related macular degeneration | |
| Nguyen et al. | Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration | |
| Altan et al. | Aetiology and clinical characteristics of uveitic glaucoma in Turkish patients | |
| US20240252497A1 (en) | Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration | |
| CN121712505A (zh) | 使用因子b抑制剂的方法 | |
| Thornit et al. | Blood–retinal barrier glycerol permeability in diabetic macular edema and healthy eyes: Estimations from Macular Volume Changes after Peroral Glycerol | |
| Vainshtein et al. | Necrotizing herpetic retinopathy: a case of delayed acute retinal necrosis presentation in a patient with uncontrolled diabetes mellitus and complications | |
| US20250295648A1 (en) | Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol | |
| Kaya et al. | Effect of perfluoropropane (C3F8) versus sulfurhexafluoride (SF6) tamponades on the retinal microvasculature after macular hole surgery | |
| Richer | Exam room, chair side evaluation of retinal edema: improving accuracy and precision for identification of subclinical diabetic macular edema | |
| Konovalova et al. | A case of acute posterior multifocal placoid pigment epitheliopathy: clinical analysis and differential diagnosis | |
| Chan et al. | Intraocular pressure changes after repeated intravitreal antivascular endothelial growth factor injections in patients with neovascular age-related macular degeneration with or without glaucoma | |
| Weiss | Active, Not Recruiting Studies | |
| Weiss | Completed Studies | |
| WO2024086555A1 (en) | Uses of anti-c3 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |